- Conditions
- Inguinal Herniorrhaphy
- Interventions
- CPL-01, Naropin 150 MG Per 20 ML Injection, Placebo
- Drug
- Lead sponsor
- Cali Pharmaceuticals LLC
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 5
- States / cities
- Sheffield, Alabama • Phoenix, Arizona • Anaheim, California + 2 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1057–1080
of 1,514
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Multiple Sclerosis
- Interventions
- HB-adMSCs, Placebo
- Biological · Drug
- Lead sponsor
- Hope Biosciences Research Foundation
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Sugar Land, Texas
- Conditions
- Substance Use Disorders, Substance Use, Methamphetamine Abuse
- Interventions
- Ketamine Hydrochloride, Midazolam Hydrochloride
- Drug
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 5
- States / cities
- San Leandro, California • Albuquerque, New Mexico • New York, New York + 2 more
- Conditions
- Genital Herpes Simplex Type 2
- Interventions
- GEN-003 Vaccine (30μg of each antigen), GEN-003 Vaccine (60μg of each antigen), Matrix-M2 Adjuvant (25μg), Matrix-M2 Adjuvant (50μg), Matrix-M2 Adjuvant (75μg), Placebo
- Biological
- Lead sponsor
- Genocea Biosciences, Inc.
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 310 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 16
- States / cities
- Birmingham, Alabama • San Diego, California • San Francisco, California + 12 more
- Conditions
- Influenza
- Interventions
- MF-59, A/Anhui/05, Placebo
- Biological · Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 637 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2011
- U.S. locations
- 10
- States / cities
- Atlanta, Georgia • Iowa City, Iowa • Baltimore, Maryland + 6 more
- Conditions
- Acute Myocardial Infarction, Moderate Renal Impairment
- Interventions
- CSL_112, Placebo
- Biological · Other
- Lead sponsor
- CSL Behring
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 83 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 13
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Concord, California + 10 more
- Conditions
- Healthy
- Interventions
- Shigella sonnei 53G
- Biological
- Lead sponsor
- PATH
- Other
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 56 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Sepsis
- Interventions
- IV fluids, Hospital Notification
- Other
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 17 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- Cambridge, Massachusetts
- Conditions
- Peripheral T-cell Lymphoma
- Interventions
- Pralatrexate Injection
- Drug
- Lead sponsor
- Spectrum Pharmaceuticals, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2017
- U.S. locations
- 3
- States / cities
- Novi, Michigan • New York, New York
- Conditions
- DENV-3 Controlled Human Infection Model
- Interventions
- AV-1 100 mg, AV-1 300 mg, AV-1 900 mg, Placebo
- Drug
- Lead sponsor
- AbViro LLC
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 85 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 3
- States / cities
- Baltimore, Maryland • Burlington, Vermont
- Conditions
- Traumatic Brain Injury
- Interventions
- Amantadine Hydrochloride, Placebo
- Drug
- Lead sponsor
- SHINKEI Therapeutics, Inc
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 13
- States / cities
- Los Angeles, California • Sacramento, California • Gainesville, Florida + 10 more
- Conditions
- Major Depressive Disorder
- Interventions
- (2R,6R)-Hydroxynorketamine hydrochloride, Placebo
- Drug
- Lead sponsor
- National Institute of Mental Health (NIMH)
- NIH
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 74 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Critical Illness, Acute Kidney Injury
- Interventions
- 0.9% Saline, Physiologically-balanced isotonic crystalloid
- Other
- Lead sponsor
- Vanderbilt University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5,381 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Acute Kidney Injury, Peritonitis, Necrotizing Soft Tissue Infection
- Interventions
- Reltecimod 0.5 mg/kg, Placebo
- Drug
- Lead sponsor
- Atox Bio Ltd
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 40
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 33 more
- Conditions
- Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
- Interventions
- Placebo, Patisiran
- Drug
- Lead sponsor
- Alnylam Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 360 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 19
- States / cities
- Los Angeles, California • Chicago, Illinois • Skokie, Illinois + 14 more
- Conditions
- Stable Coronary Artery Disease
- Interventions
- Selatogrel, Placebo
- Drug
- Lead sponsor
- Viatris Innovation GmbH
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 346 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018
- U.S. locations
- 7
- States / cities
- Jacksonville, Florida • Tampa, Florida • Chicago, Illinois + 4 more
- Conditions
- Pneumonia, Hypoxemia, Acute Respiratory Failure, COVID-19 Pneumonia
- Interventions
- Inhaled budesonide and formoterol, Inhaled placebo
- Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 465 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 12
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 8 more
- Conditions
- Glabellar Frown Lines
- Interventions
- Botulinum Toxin A, Placebo
- Drug
- Lead sponsor
- Croma-Pharma GmbH
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 410 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Acute Ischemic Stroke
- Interventions
- Intra-arterial Tenecteplase, Intra-arterial Saline
- Drug
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Charlotte, North Carolina
- Conditions
- Chikungunya Fever, Chikungunya Virus, Chikungunya
- Interventions
- HydroVax-005 CHIKV, Placebo
- Biological · Other
- Lead sponsor
- Najit Technologies, Inc.
- Industry
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- West Nile Viral Infection
- Interventions
- HydroVax-001, Placebo
- Biological · Other
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 96 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- PIV5-vectored RSV Vaccine (BLB-201) Low Dose, PIV5-vectored RSV Vaccine (BLB-201) High Dose, Placebo
- Biological · Drug
- Lead sponsor
- Blue Lake Biotechnology Inc.
- Industry
- Eligibility
- 6 Months to 5 Years
- Enrollment
- 137 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2028
- U.S. locations
- 18
- States / cities
- La Mesa, California • Modesto, California • San Diego, California + 14 more
- Conditions
- HIV Infections
- Interventions
- ALVAC-HIV (vCP2438), Bivalent subtype C gp120/MF59, Bivalent subtype C gp120/AS01(B), Placebo
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 160 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2020
- U.S. locations
- 9
- States / cities
- San Francisco, California • Decatur, Georgia • Boston, Massachusetts + 5 more
- Conditions
- Dry Eye
- Interventions
- Intravenous Immune Globulin (IVIG), Placebo
- Drug
- Lead sponsor
- Sandeep Jain, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- Chicago, Illinois